Viridian Therapeutics Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Viridian Therapeutics Inc has an operating margin of -99018.2%, meaning the company retains $-99018 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -81035.0% the prior year.
Viridian Therapeutics Inc's revenue declined 3.8% year-over-year, from $314K to $302K. This contraction results in a growth score of 18/100.
Viridian Therapeutics Inc carries a low D/E ratio of 0.03, meaning only $0.03 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 15.43, Viridian Therapeutics Inc holds $15.43 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Viridian Therapeutics Inc generated -$232.3M in operating cash flow, capex of $511K consumed most of it, leaving -$232.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Viridian Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Viridian Therapeutics Inc generates $0.86 in operating cash flow (-$232.3M OCF vs -$269.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Viridian Therapeutics Inc earns $-98.2 in operating income for every $1 of interest expense (-$299.0M vs $3.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Viridian Therapeutics Inc (VRDN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Viridian Therapeutics Inc generated $302K in revenue in fiscal year 2024. This represents a decrease of 3.8% from the prior year.
Viridian Therapeutics Inc's EBITDA was -$298.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 17.6% from the prior year.
Viridian Therapeutics Inc generated -$232.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 25.8% from the prior year.
Viridian Therapeutics Inc reported -$269.9M in net income in fiscal year 2024. This represents a decrease of 13.6% from the prior year.
Viridian Therapeutics Inc held $99.6M in cash against $20.6M in long-term debt as of fiscal year 2024.
Viridian Therapeutics Inc had 81M shares outstanding in fiscal year 2024. This represents an increase of 50.0% from the prior year.
Viridian Therapeutics Inc's operating margin was -99018.2% in fiscal year 2024, reflecting core business profitability. This is down 17983.2 percentage points from the prior year.
Viridian Therapeutics Inc's net profit margin was -89387.1% in fiscal year 2024, showing the share of revenue converted to profit. This is down 13675.6 percentage points from the prior year.
Viridian Therapeutics Inc invested $238.3M in research and development in fiscal year 2024. This represents an increase of 49.1% from the prior year.
Viridian Therapeutics Inc invested $511K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 43.1% from the prior year.
VRDN Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $70.6M+93993.3% | $75K+4.2% | $72K0.0% | $72K0.0% | $72K0.0% | $72K0.0% | $72K0.0% | $72K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $86.3M-0.4% | $86.6M+12.7% | $76.8M+6.8% | $72.0M+28.1% | $56.2M+37.2% | $40.9M+6.2% | $38.6M+26.9% | $30.4M |
| SG&A Expenses | $24.3M+20.3% | $20.2M+18.2% | $17.1M+9.7% | $15.6M-3.0% | $16.1M+6.9% | $15.0M-54.5% | $33.0M+57.8% | $20.9M |
| Operating Income | -$40.0M+62.5% | -$106.8M-13.7% | -$93.9M-7.3% | -$87.5M-21.2% | -$72.2M-29.1% | -$55.9M+21.8% | -$71.5M-39.5% | -$51.2M |
| Interest Expense | $560K+8.9% | $514K-12.3% | $586K-56.0% | $1.3M+123.3% | $597K+1.7% | $587K-30.7% | $847K+41.2% | $600K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$34.6M+65.7% | -$100.7M-15.9% | -$86.9M-9.0% | -$79.7M-22.7% | -$65.0M-33.9% | -$48.5M+27.4% | -$66.9M-40.3% | -$47.7M |
| EPS (Diluted) | N/A | N/A | N/A | $-1.15-12.7% | $-1.02-29.1% | $-0.79+41.0% | $-1.34-22.9% | $-1.09 |
VRDN Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $577.1M-0.9% | $582.3M-11.9% | $661.0M-11.0% | $742.4M+26.8% | $585.7M-7.1% | $630.4M+28.5% | $490.4M+49.2% | $328.8M |
| Current Assets | $571.9M-1.2% | $578.8M-11.9% | $657.2M-11.0% | $738.5M+27.0% | $581.7M-7.2% | $626.8M+28.8% | $486.5M+50.2% | $323.8M |
| Cash & Equivalents | $169.6M+44.6% | $117.3M+1.0% | $116.2M+16.7% | $99.6M-7.5% | $107.7M+17.5% | $91.6M-10.9% | $102.8M-7.9% | $111.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $74.2M+10.4% | $67.2M+18.8% | $56.5M-20.1% | $70.8M+25.6% | $56.3M+17.7% | $47.9M-1.1% | $48.4M+7.1% | $45.2M |
| Current Liabilities | $50.7M-3.6% | $52.6M+55.9% | $33.7M-29.6% | $47.9M+30.2% | $36.8M+40.7% | $26.1M-1.9% | $26.6M+14.6% | $23.2M |
| Long-Term Debt | $20.9M+69.1% | $12.4M-40.3% | $20.7M+0.5% | $20.6M+17.7% | $17.5M-14.0% | $20.3M+0.6% | $20.2M+1.0% | $20.0M |
| Total Equity | $503.0M-2.4% | $515.2M-14.8% | $604.5M-10.0% | $671.6M+26.9% | $529.3M-9.1% | $582.5M+31.8% | $442.0M+55.9% | $283.6M |
| Retained Earnings | -$1.2B-2.9% | -$1.2B-9.3% | -$1.1B-8.7% | -$995.9M-18.6% | -$839.4M-8.4% | -$774.5M-6.7% | -$725.9M-10.1% | -$659.0M |
VRDN Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$84.6M-12.3% | -$75.4M+18.7% | -$92.7M-26.3% | -$73.3M-59.2% | -$46.1M-1.8% | -$45.2M-19.0% | -$38.0M+2.5% | -$39.0M |
| Capital Expenditures | $127K+202.4% | $42K-51.2% | $86K-24.6% | $114K+9.6% | $104K | $0-100.0% | $48K-88.1% | $404K |
| Free Cash Flow | -$84.7M-12.4% | -$75.4M+18.7% | -$92.7M-26.3% | -$73.4M-59.1% | -$46.2M-2.1% | -$45.2M-18.9% | -$38.0M+3.4% | -$39.4M |
| Investing Cash Flow | $126.1M+66.5% | $75.7M-24.3% | $100.1M+259.0% | -$62.9M-201.5% | $62.0M+143.3% | -$143.0M+15.7% | -$169.7M-453.3% | $48.0M |
| Financing Cash Flow | $10.9M+1321.1% | $764K-91.7% | $9.2M-74.1% | $35.5M+32792.6% | $108K-99.9% | $177.1M-11.0% | $198.9M+1187.1% | $15.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VRDN Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -56.7%+142299.3pp | -142356.0%-11986.6pp | -130369.4%-8881.9pp | -121487.5%-21227.8pp | -100259.7%-22625.0pp | -77634.7%+21640.3pp | -99275.0%-28130.6pp | -71144.4% |
| Net Margin | -49.0%+134264.3pp | -134313.3%-13602.2pp | -120711.1%-9981.9pp | -110729.2%-20461.1pp | -90268.1%-22848.6pp | -67419.4%+25441.7pp | -92861.1%-26666.7pp | -66194.4% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -6.0%+11.3pp | -17.3%-4.1pp | -13.2%-2.4pp | -10.7%+0.4pp | -11.1%-3.4pp | -7.7%+5.9pp | -13.6%+0.9pp | -14.5% |
| Current Ratio | 11.28+0.3 | 11.01-8.5 | 19.49+4.1 | 15.43-0.4 | 15.82-8.2 | 23.99+5.7 | 18.26+4.3 | 13.93 |
| Debt-to-Equity | 0.04+0.0 | 0.02-0.0 | 0.030.0 | 0.030.0 | 0.030.0 | 0.03-0.0 | 0.05-0.0 | 0.07 |
| FCF Margin | -120.1%+100433.3pp | -100553.3%+28250.8pp | -128804.2%-26795.8pp | -102008.3%-37894.4pp | -64113.9%-1304.2pp | -62809.7%-9965.3pp | -52844.4%+1859.7pp | -54704.2% |
Similar Companies
Frequently Asked Questions
What is Viridian Therapeutics Inc's annual revenue?
Viridian Therapeutics Inc (VRDN) reported $302K in total revenue for fiscal year 2024. This represents a -3.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Viridian Therapeutics Inc's revenue growing?
Viridian Therapeutics Inc (VRDN) revenue declined by 3.8% year-over-year, from $314K to $302K in fiscal year 2024.
Is Viridian Therapeutics Inc profitable?
No, Viridian Therapeutics Inc (VRDN) reported a net income of -$269.9M in fiscal year 2024, with a net profit margin of -89387.1%.
What is Viridian Therapeutics Inc's EBITDA?
Viridian Therapeutics Inc (VRDN) had EBITDA of -$298.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Viridian Therapeutics Inc have?
As of fiscal year 2024, Viridian Therapeutics Inc (VRDN) had $99.6M in cash and equivalents against $20.6M in long-term debt.
What is Viridian Therapeutics Inc's operating margin?
Viridian Therapeutics Inc (VRDN) had an operating margin of -99018.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Viridian Therapeutics Inc's net profit margin?
Viridian Therapeutics Inc (VRDN) had a net profit margin of -89387.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Viridian Therapeutics Inc's free cash flow?
Viridian Therapeutics Inc (VRDN) generated -$232.8M in free cash flow during fiscal year 2024. This represents a -25.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Viridian Therapeutics Inc's operating cash flow?
Viridian Therapeutics Inc (VRDN) generated -$232.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Viridian Therapeutics Inc's total assets?
Viridian Therapeutics Inc (VRDN) had $742.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Viridian Therapeutics Inc's capital expenditures?
Viridian Therapeutics Inc (VRDN) invested $511K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Viridian Therapeutics Inc spend on research and development?
Viridian Therapeutics Inc (VRDN) invested $238.3M in research and development during fiscal year 2024.
How many shares does Viridian Therapeutics Inc have outstanding?
Viridian Therapeutics Inc (VRDN) had 81M shares outstanding as of fiscal year 2024.
What is Viridian Therapeutics Inc's current ratio?
Viridian Therapeutics Inc (VRDN) had a current ratio of 15.43 as of fiscal year 2024, which is generally considered healthy.
What is Viridian Therapeutics Inc's debt-to-equity ratio?
Viridian Therapeutics Inc (VRDN) had a debt-to-equity ratio of 0.03 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Viridian Therapeutics Inc's return on assets (ROA)?
Viridian Therapeutics Inc (VRDN) had a return on assets of -36.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Viridian Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Viridian Therapeutics Inc (VRDN) had $99.6M in cash against an annual operating cash burn of $232.3M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Viridian Therapeutics Inc's Piotroski F-Score?
Viridian Therapeutics Inc (VRDN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Viridian Therapeutics Inc's earnings high quality?
Viridian Therapeutics Inc (VRDN) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Viridian Therapeutics Inc cover its interest payments?
Viridian Therapeutics Inc (VRDN) has an interest coverage ratio of -98.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Viridian Therapeutics Inc?
Viridian Therapeutics Inc (VRDN) scores 44 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.